Entecavir Mylan

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

entecavir monohydrate

Available from:

Mylan Pharmaceuticals Limited

ATC code:

J05AF10

INN (International Name):

entecavir

Therapeutic group:

Antivirals for systemic use

Therapeutic area:

Hepatitis B

Therapeutic indications:

Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to

Product summary:

Revision: 6

Authorization status:

Authorised

Authorization date:

2017-09-18

Patient Information leaflet

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
ENTECAVIR VIATRIS 0.5 MG FILM-COATED TABLETS
ENTECAVIR VIATRIS 1 MG FILM-COATED TABLETS
entecavir
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Entecavir Viatris is and what it is used for
2.
What you need to know before you take Entecavir Viatris
3.
How to take Entecavir Viatris
4.
Possible side effects
5.
How to store Entecavir Viatris
6.
Contents of the pack and other information
1.
WHAT ENTECAVIR VIATRIS IS AND WHAT IT IS USED FOR
ENTECAVIR VIATRIS TABLETS ARE ANTI-VIRAL MEDICINES, USED TO TREAT
CHRONIC (LONG TERM) HEPATITIS B
VIRUS (HBV) INFECTION IN ADULTS.
Entecavir Viatris can be used in people whose liver is damaged but
still functions properly (compensated liver disease) and in people
whose liver is damaged and does not
function properly (decompensated liver disease).
ENTECAVIR VIATRIS TABLETS ARE ALSO USED TO TREAT CHRONIC (LONG TERM)
HBV INFECTION IN CHILDREN
AND ADOLESCENTS AGED 2 YEARS TO LESS THAN 18 YEARS.
Entecavir Viatris can be used in children whose
liver is damaged but still functions properly (compensated liver
disease).
Infection by the hepatitis B virus can lead to damage to the liver.
Entecavir Viatris reduces the amount
of virus in your body, and improves the condition of the liver.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTECAVIR VIATRIS
_ _
DO NOT TAKE ENTECAVIR VIATRIS

IF YOU ARE ALLERGIC (HYPERSENSITIVE)
to entecavir or any of the other ingredients of this medicine
(listed in section 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Entecavir Viatris 0.5 mg film-coated tablets
Entecavir Viatris 1 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Entecavir Viatris 0.5 mg film-coated tablets
Each film-coated tablet contains entecavir monohydrate equivalent to
0.5 mg entecavir.
Entecavir Viatris 1 mg film-coated tablets
Each film-coated tablet contains entecavir monohydrate equivalent to 1
mg entecavir.
Excipient with known effect
_Entecavir Viatris 0.5 mg film-coated tablets _
Each film-coated tablet contains 62.5 mg lactose monohydrate.
_ _
_Entecavir Viatris 1 mg film-coated tablets _
Each film-coated tablet contains 125 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Entecavir Viatris 0.5 mg film-coated tablets
White, film-coated, round, biconvex, beveled edge tablet debossed with
“M” on one side and “EA” on
the other side. Diameter: approximately 6.8 mm.
_ _
Entecavir Viatris 1 mg film-coated tablets
_ _
_ _
White, film-coated, round, biconvex, beveled edge tablet debossed with
“M” on one side and “EB” on
the other side. Diameter: approximately 8.8 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Entecavir Viatris is indicated for the treatment of chronic hepatitis
B virus (HBV) infection (see
section 5.1) in adults with:

compensated liver disease and evidence of active viral replication,
persistently elevated
serum alanine aminotransferase (ALT) levels and histological evidence
of active
inflammation and/or fibrosis.

decompensated liver disease (see section 4.4)
For both compensated and decompensated liver disease, this indication
is based on clinical trial data in
nucleoside naive patients with HBeAg positive and HBeAg negative HBV
infection. With respect to
patients with lamivudine-refractory hepatitis B, see sections 4.2, 4.4
and 5.1.
3
Entecavir Viatris is also indicated for the treatment of chronic HBV
infection in nucleoside naive
paediatr
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-01-2024
Public Assessment Report Public Assessment Report Bulgarian 26-10-2017
Patient Information leaflet Patient Information leaflet Spanish 16-01-2024
Public Assessment Report Public Assessment Report Spanish 26-10-2017
Patient Information leaflet Patient Information leaflet Czech 16-01-2024
Public Assessment Report Public Assessment Report Czech 26-10-2017
Patient Information leaflet Patient Information leaflet Danish 16-01-2024
Public Assessment Report Public Assessment Report Danish 26-10-2017
Patient Information leaflet Patient Information leaflet German 16-01-2024
Public Assessment Report Public Assessment Report German 26-10-2017
Patient Information leaflet Patient Information leaflet Estonian 16-01-2024
Public Assessment Report Public Assessment Report Estonian 26-10-2017
Patient Information leaflet Patient Information leaflet Greek 16-01-2024
Public Assessment Report Public Assessment Report Greek 26-10-2017
Patient Information leaflet Patient Information leaflet French 16-01-2024
Public Assessment Report Public Assessment Report French 26-10-2017
Patient Information leaflet Patient Information leaflet Italian 16-01-2024
Public Assessment Report Public Assessment Report Italian 26-10-2017
Patient Information leaflet Patient Information leaflet Latvian 16-01-2024
Public Assessment Report Public Assessment Report Latvian 26-10-2017
Patient Information leaflet Patient Information leaflet Lithuanian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-01-2024
Public Assessment Report Public Assessment Report Lithuanian 26-10-2017
Patient Information leaflet Patient Information leaflet Hungarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 16-01-2024
Public Assessment Report Public Assessment Report Hungarian 26-10-2017
Patient Information leaflet Patient Information leaflet Maltese 16-01-2024
Public Assessment Report Public Assessment Report Maltese 26-10-2017
Patient Information leaflet Patient Information leaflet Dutch 16-01-2024
Public Assessment Report Public Assessment Report Dutch 26-10-2017
Patient Information leaflet Patient Information leaflet Polish 16-01-2024
Public Assessment Report Public Assessment Report Polish 26-10-2017
Patient Information leaflet Patient Information leaflet Portuguese 16-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 16-01-2024
Public Assessment Report Public Assessment Report Portuguese 26-10-2017
Patient Information leaflet Patient Information leaflet Romanian 16-01-2024
Public Assessment Report Public Assessment Report Romanian 26-10-2017
Patient Information leaflet Patient Information leaflet Slovak 16-01-2024
Public Assessment Report Public Assessment Report Slovak 26-10-2017
Patient Information leaflet Patient Information leaflet Slovenian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 16-01-2024
Public Assessment Report Public Assessment Report Slovenian 26-10-2017
Patient Information leaflet Patient Information leaflet Finnish 16-01-2024
Public Assessment Report Public Assessment Report Finnish 26-10-2017
Patient Information leaflet Patient Information leaflet Swedish 16-01-2024
Public Assessment Report Public Assessment Report Swedish 26-10-2017
Patient Information leaflet Patient Information leaflet Norwegian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 16-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 16-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 16-01-2024
Patient Information leaflet Patient Information leaflet Croatian 16-01-2024
Public Assessment Report Public Assessment Report Croatian 26-10-2017

Search alerts related to this product